GSK, CureVac collaborate on next-gen multivalent mRNA COVID-19 vaccines

By The Science Advisory Board staff writers

February 3, 2021 -- Glaxo Smith Kline (GSK) and CureVac have entered into a collaboration to jointly develop next-generation messenger RNA (mRNA) vaccines for COVID-19, with the potential for a multivalent approach to address emerging variants in one vaccine.

Through the more than $180 million co-development agreement, GSK and CureVac will contribute resources and expertise to the research, development, and manufacture of a number of novel mRNA vaccine candidates, including both multivalent and monovalent approaches. The companies seek to provide broader protection against a variety of SARS-CoV-2 variants and enable a quick response to new variants in the future.

The work will begin immediately, with the goal of introducing a vaccine in 2022, subject to regulatory approval.

Under the agreement, GSK will be the marketing authorization holder for the next generation vaccine, except in Switzerland, and will have exclusive rights to develop, manufacture, and commercialize a next-generation COVID-19 vaccine in all countries with the exception of Germany, Austria, and Switzerland. GSK will make an upfront payment of 75 million euros ($90.2 million U.S.) and a further milestone payment of 75 million euros ($90.2 million U.S.), conditional on the achievement of specific milestones.

GSK will also support the manufacture of up to 100 million doses of CureVac's first generation COVID-19 vaccine candidate, CVnCoV, in 2021. CVnCoV is currently in phase IIB/III clinical trials. The vaccine was developed on CureVac's platform, which is adapted to designing multivalent vaccines with balanced immune responses and a low dose of mRNA.

CureVac, Bayer partner on COVID-19 vaccine
CureVac and Bayer have signed a collaboration and services agreement to develop a new class of medicines based on messenger RNA, starting with CureVac's...
Vir, GSK begin trial for COVID-19 monoclonal antibody
Vir Biotechnology and GlaxoSmithKline (GSK) have dosed the first patient in a new subtrial of the U.S. National Institutes of Health's Accelerating COVID-19...
Sanofi, GSK COVID-19 vaccine program delayed by responses in elderly
Sanofi and GlaxoSmithKline (GSK) are delaying their adjuvanted recombinant protein-based COVID-19 vaccine program to improve the vaccine's immune response...
EU secures 225M doses of CureVac COVID-19 vaccine
The European Commission approved a fifth contract with CureVac for the initial purchase of 225 million doses on behalf of all European Union (EU)...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter